Since the start of the COVID-19 outbreak, pharmaceutical companies and research groups have focused on the development of vaccines and antiviral drugs against SARS-CoV-2. Here, we apply a drug repurposing strategy to identify drug candidates that are able to block the entrance of the virus into human cells. By combining virtual screening with in vitro pseudovirus assays and antiviral assays in Human Lung Tissue (HLT) cells, we identify entrectinib as a potential antiviral drug.
All Keywords
【저자키워드】 COVID-19, Drug repurposing, SARS-CoV-2, Virtual screening, viral cell entry assays, 【초록키워드】 Vaccine, Human, antiviral drugs, Virtual screening, in vitro, virus, antiviral drug, COVID-19 outbreak, cells, Research, Antiviral assays, group, antiviral assay, pharmaceutical companies, entrectinib, drug candidates, human cells, drug candidate, pseudovirus assays, vitro pseudovirus assays, pseudovirus assay, identify, 【제목키워드】 Human,
【저자키워드】 COVID-19, Drug repurposing, SARS-CoV-2, Virtual screening, viral cell entry assays, 【초록키워드】 Vaccine, Human, antiviral drugs, Virtual screening, in vitro, virus, antiviral drug, COVID-19 outbreak, cells, Research, Antiviral assays, group, antiviral assay, pharmaceutical companies, entrectinib, drug candidates, human cells, drug candidate, pseudovirus assays, vitro pseudovirus assays, pseudovirus assay, identify, 【제목키워드】 Human,
COVID-19 발병이 시작된 이후 제약 회사와 연구 그룹은 SARS-CoV-2에 대한 백신 및 항바이러스제 개발에 집중해 왔습니다. 여기에서 우리는 인간 세포로의 바이러스 유입을 차단할 수 있는 약물 후보를 식별하기 위해 약물 용도 변경 전략을 적용합니다. 인간 폐 조직(HLT) 세포에서 가상 스크리닝과 시험관 내 슈도바이러스 분석 및 항바이러스 분석을 결합하여 엔트렉티닙을 잠재적인 항바이러스 약물로 식별합니다.